INLYTA TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

AXITINIB

Saadav alates:

PFIZER CANADA ULC

ATC kood:

L01EK01

INN (Rahvusvaheline Nimetus):

AXITINIB

Annus:

7MG

Ravimvorm:

TABLET

Koostis:

AXITINIB 7MG

Manustamisviis:

ORAL

Ühikuid pakis:

28/56/60

Retsepti tüüp:

Prescription

Terapeutiline ala:

ANTINEOPLASTIC AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0153228004; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2014-03-24

Toote omadused

_ _
_INLYTA_
®
_ (axitinib) Product Monograph _
_Page 1 of 52_
PRODUCT MONOGRAPH
Pr
INLYTA
®
Axitinib
Tablets, 1 mg, 3 mg, 5 mg and 7 mg
Kinase Inhibitor, Anti-Tumour Agent
®
Pfizer Products ULC
17,300 Trans-Canada Highway
Kirkland, Quebec
H9J 2M5
©
Pfizer Canada ULC, 2021
Date of Revision:
28 September 2021
Submission
Control No: 245813
_ _
_INLYTA_
®
_ (axitinib) Product Monograph _
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
........................................................................
3
CONTRAINDICATIONS.............................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................
5
ADVERSE REACTIONS
............................................................................................14
DRUG INTERACTIONS
............................................................................................25
DOSAGE AND ADMINISTRATION
.........................................................................26
OVERDOSAGE
..........................................................................................................29
ACTION AND CLINICAL PHARMACOLOGY
.........................................................29
STORAGE AND STABILITY
....................................................................................31
DOSAGE FORMS, COMPOSITION AND
PACKAGING...........................................32
PART II: SCIENTIFIC INFORMATION
.........................................................................
34
PHARMACEUTICAL INFORMATION
.....................................................................34
CLINICAL
TRIALS....................................................................................................35
DETAILED PHARMACOLOGY
.........................